|
|
|
|
| LEADER |
00000cam a2200000 a 4500 |
| 001 |
3349349 |
| 003 |
ICU |
| 005 |
20030526124200.0 |
| 008 |
970903s1998 nyua b 001 0 eng c |
| 010 |
|
|
|a 97036795
|
| 020 |
|
|
|a 0824795164 (acid-free paper)
|
| 035 |
|
|
|a (NhCcYBP)YBT 97036795 //r98
|
| 035 |
|
|
|a (NhCcYBP)YBP98260104559
|
| 040 |
|
|
|a DNLM/DLC
|c DLC
|d DLC
|d OrLoB-B
|d OCoLC
|
| 050 |
0 |
0 |
|a RC927
|b .T498 1998
|
| 060 |
1 |
0 |
|a WE 346 T398 1998
|
| 082 |
0 |
0 |
|a 616.7/23061
|2 21
|
| 245 |
0 |
0 |
|a Therapy of systemic rheumatic disorders /
|c edited by Leo B.A. van de Putte ... [et al.].
|
| 260 |
|
|
|a New York :
|b M. Dekker,
|c c1998.
|
| 300 |
|
|
|a xii, 709 p. :
|b ill. ;
|c 26 cm.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|0 http://id.loc.gov/vocabulary/contentTypes/txt
|
| 337 |
|
|
|a unmediated
|b n
|2 rdamedia
|0 http://id.loc.gov/vocabulary/mediaTypes/n
|
| 338 |
|
|
|a volume
|b nc
|2 rdacarrier
|0 http://id.loc.gov/vocabulary/carriers/nc
|
| 504 |
|
|
|a Includes bibliographical references and index.
|
| 505 |
0 |
0 |
|g I.
|t Rheumatoid Arthritis.
|g 1.
|t Pathogenic Mechanisms as Targets for Therapy in Rheumatoid Arthritis /
|r N. J. Zvaifler.
|g 2.
|t Clinical Assessments in Rheumatoid Arthritis /
|r Piet L. C. M. van Riel, Anke M. van Gestel and Maarten Boers [et al.].
|g 3.
|t Prognostic Markers for Rheumatoid Arthritis /
|r Michael J. Green, Charles Richardson and Paul Emery.
|g 4.
|t Clinical Trials Revisited /
|r Harold E. Paulus and Ken J. Bulpitt.
|g 5.
|t Second-line Agent Treatment: When and Whom /
|r David L. Scott.
|g 6.
|t Aggressive Treatment of Rheumatoid Arthritis: When, Whom, and How /
|r Graciela S. Alarcon.
|g 7.
|t Hydroxychloroquine /
|r Howard Bird and Ann W. Morgan.
|g 8.
|t D-Penicillamine /
|r Howard Bird and Ann W. Morgan.
|g 9.
|t Gold Therapy /
|r Anne McEntegart and Hilary A. Capell.
|g 10.
|t Sulfasalazine /
|r Maxime Dougados.
|g 11.
|t Methotrexate /
|r Michael Ahern.
|g 12.
|t Newer Second-line Agents: Cyclosporin /
|r Theresa Podrebarac and Peter Tugwell.
|g 13.
|t Cytotoxics (Azathioprine, Chlorambucil, and Cyclophosphamide) /
|r Philip J. Clements.
|g 14.
|t Combination Disease-modifying Antirheumatic Drug Therapy in Rheumatoid Arthritis /
|r H. James Williams.
|g 15.
|t When to Stop Second-line Drugs: Risk/Benefit Ratio of Continuation Versus Cessation in Patients with Rheumatoid Arthritis in Remission /
|r S. ten Wolde and B. A. C. Dijkmans.
|g 16.
|t Do Corticosteroids Have a Disease-modifying Role in Rheumatoid Arthritis? /
|r Keith Lim and John R. Kirwan.
|g 17.
|t Biological Agents Directed Against Cell Surface Antigens in the Treatment of Rheumatoid Arthritis /
|r Ferdinand C. Breedveld.
|g 18.
|t The Clinical Application of Cytokine Blockade in the Therapy of Rheumatoid Arthritis /
|r Diana Davis, Michael Elliott and Ravinder Maini.
|g 19.
|t Local Therapy for Inflammatory Arthritis /
|r John Edmonds.
|g 20.
|t Antibiotic Treatment of Rheumatoid Arthritis /
|r Christopher G. Jackson --
|g II.
|t Other Polyarthritides.
|g 21.
|t Management of Spondylarthropathy /
|r Maxime Dougados, Michel Revel and Muhammad Asim Khan.
|g 22.
|t Therapy of Systemic Rheumatic Disorders in Children /
|r Anne-Marie Prieur.
|g 23.
|t Palindromic Rheumatism and Recurrent Arthritis /
|r Pierre-Andre Guerne.
|g 24.
|t Adult Still's Disease /
|r Pierre-Andre Guerne --
|g III.
|t Collagen Vascular Diseases.
|g 25.
|t Systemic Lupus Erythematosus /
|r Naomi F. Rothfield and Ann Parke.
|g 26.
|t Therapy of Systemic Sclerosis /
|r Carol Mary Black and Christopher P. Denton.
|g 27.
|t Eosinophilic Fasciitis and Eosinophilia Myalgia Syndrome /
|r Daniel J. Clauw.
|g 28.
|t Collagen Vascular Diseases: Polymyositis, Dermatomyositis, and Inclusion Body Myositis /
|r Robert F. Spiera and Lawrence Kagen.
|g 29.
|t Taxonomy of the Vasculitis Syndromes /
|r C. G. M. Kallenberg.
|g 30.
|t Therapy of Wegener's Granulomatosis /
|r C. G. M. Kallenberg.
|g 31.
|t Therapy of Other Vasculitis Syndromes /
|r George D. Kitas, Paul A. Bacon and Raashid Luqmani.
|g 32.
|t Therapy of Sjogren's Syndrome /
|r Panayiotis G. Vlachoyiannopoulos and Haralampos M. Moutsopoulos.
|g 33.
|t Management of the Antiphospholipid Syndrome /
|r E. Nigel Harris.
|g 34.
|t Second-Line Agents in Rheumatic Diseases During Pregnancy /
|r Dafna D. Gladman and Gideon Koren.
|g 35.
|t Cytotoxic Drugs and the Risk for Malignancies /
|r Grant W. Cannon.
|
| 650 |
|
0 |
|a Rheumatism
|x Chemotherapy.
|0 http://id.loc.gov/authorities/subjects/sh85113644
|
| 650 |
|
0 |
|a Arthritis
|x Chemotherapy.
|0 http://id.loc.gov/authorities/subjects/sh85008123
|
| 650 |
|
0 |
|a Musculoskeletal system
|x Diseases
|x Chemotherapy.
|
| 650 |
1 |
2 |
|a Arthritis, Rheumatoid
|x drug therapy.
|
| 650 |
2 |
2 |
|a Vasculitis
|x drug therapy.
|
| 650 |
2 |
2 |
|a Arthritis
|x drug therapy.
|
| 650 |
2 |
2 |
|a Antirheumatic Agents
|x therapeutic use.
|
| 650 |
|
7 |
|a Arthritis
|x Chemotherapy.
|2 fast
|0 http://id.worldcat.org/fast/fst00817100
|
| 650 |
|
7 |
|a Rheumatism
|x Chemotherapy.
|2 fast
|0 http://id.worldcat.org/fast/fst01097004
|
| 700 |
1 |
|
|a Putte, Levinus Boudewijn Abraham van de,
|d 1941-
|0 http://id.loc.gov/authorities/names/n87804369
|
| 901 |
|
|
|a ToCBNA
|
| 903 |
|
|
|a HeVa
|
| 035 |
|
|
|a (OCoLC)37616760
|
| 929 |
|
|
|a cat
|
| 999 |
f |
f |
|i 36376386-f68e-5b83-81ea-e2aa67716aca
|s d601e23e-2f6b-53a8-80e7-19ea466e06f8
|
| 928 |
|
|
|t Library of Congress classification
|a RC927 .T498 1998
|l ASR
|c ASR-SciASR
|i 6197844
|
| 927 |
|
|
|t Library of Congress classification
|a RC927 .T498 1998
|l ASR
|c ASR-SciASR
|e CRERAR
|b 48353511
|i 5732756
|
